Reduced natural killer cell activity and OKT4/OKT8 ratio in epileptic patients. 1986

N C Margaretten, and R P Warren

A number of immune abnormalities have been found in epileptic patients. Several, but not all, of these defects appear to be related to the toxic effects of antiseizure medications. To study the basis of immune abnormalities in epilepsy, various populations and subsets of peripheral blood mononuclear cells (PBMC) from epileptic patients were enumerated and their functions examined. Reduced natural killer cell activity was found in the patients and their siblings. Enumeration of the PBMC showed a lower proportions of Leu 11+ cells in some of the patients which may account for the lower natural killer activity. A reduced ratio of OKT4+/OKT8+ cells was also found in the patients. Responses of patient PBMC to the T-cell mitogens phytohemagglutinin, concanavalin A and the B-cell mitogen pokeweed mitogen were unchanged as were the total number of rosette-forming cells in the patients. The results provide more evidence for a genetic basis for some of the immune abnormalities in epileptic patients.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010835 Phytohemagglutinins Mucoproteins isolated from the kidney bean (Phaseolus vulgaris); some of them are mitogenic to lymphocytes, others agglutinate all or certain types of erythrocytes or lymphocytes. They are used mainly in the study of immune mechanisms and in cell culture. Kidney Bean Lectin,Kidney Bean Lectins,Lectins, Kidney Bean,Phaseolus vulgaris Lectin,Phaseolus vulgaris Lectins,Phytohemagglutinin,Hemagglutinins, Plant,Lectin, Kidney Bean,Lectin, Phaseolus vulgaris,Lectins, Phaseolus vulgaris,Plant Hemagglutinins
D011043 Pokeweed Mitogens Proteins isolated from the roots of the pokeweed, Phytolacca americana, that agglutinate some erythrocytes, stimulate mitosis and antibody synthesis in lymphocytes, and induce activation of plasma cells. Lectins, Pokeweed,Pokeweed Lectin,Pokeweed Lectins,Pokeweed Mitogen,Pokeweed Mitogen Isolectin,Isolectin, Pokeweed Mitogen,Lectin, Pokeweed,Mitogen Isolectin, Pokeweed,Mitogen, Pokeweed,Mitogens, Pokeweed
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003208 Concanavalin A A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.
D003601 Cytotoxicity Tests, Immunologic The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitized lymphocyte, an antibody, or complement. AHG-CDC Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Tests,Microcytotoxicity Tests,Anti Human Globulin Complement Dependent Cytotoxicity Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunologic,Cytotoxicity Tests, Anti-Human Globulin Complement-Dependent,Cytotoxicity Tests, Immunological,Immunologic Cytotoxicity Test,Immunologic Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin-Augmented,Lymphocytotoxicity Tests, Antiglobulin-Augmented,Microcytotoxicity Test,AHG CDC Tests,AHG-CDC Test,Anti Human Globulin Complement Dependent Cytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunological,Cytotoxicity Tests, Anti Human Globulin Complement Dependent,Immunological Cytotoxicity Test,Immunological Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin Augmented,Lymphocytotoxicity Tests, Antiglobulin Augmented
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders

Related Publications

N C Margaretten, and R P Warren
July 1989, British journal of addiction,
N C Margaretten, and R P Warren
December 1988, Minerva medica,
N C Margaretten, and R P Warren
January 1985, Bollettino dell'Istituto sieroterapico milanese,
N C Margaretten, and R P Warren
January 1985, [Rinsho ketsueki] The Japanese journal of clinical hematology,
N C Margaretten, and R P Warren
February 1985, Journal of clinical & laboratory immunology,
N C Margaretten, and R P Warren
January 1985, Leukemia research,
N C Margaretten, and R P Warren
June 1986, European journal of cancer & clinical oncology,
N C Margaretten, and R P Warren
November 1981, Bollettino dell'Istituto sieroterapico milanese,
N C Margaretten, and R P Warren
June 1987, The American review of respiratory disease,
N C Margaretten, and R P Warren
June 1991, British journal of cancer,
Copied contents to your clipboard!